NASDAQ: FRTX - Fresh Tracks Therapeutics, Inc.

Rentabilité sur six mois: +31.69%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions Fresh Tracks Therapeutics, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States.

plus de détails
The company develops FRTX-02 (BBI-02), an oral DYRK1A inhibitor that is completed Phase 1 clinical trials for the treatment of autoimmune and inflammatory diseases; FRTX-10 (BBI-10), a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases; and FRTX-03, a topical DYRK1A inhibitor for the treatment of mild-to-moderate skin conditions, as well as next-generation kinase inhibitors. Fresh Tracks Therapeutics, Inc. has license and collaboration agreements with Carna Biosciences, Inc., and Voronoi Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2022-09-08
ISIN US10802T2042
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.frtx.com
Цена ао 0.94
Changement de prix par jour: -0.5319% (0.94)
Changement de prix par semaine: -0.5319% (0.94)
Changement de prix par mois: -0.5319% (0.94)
Changement de prix sur 3 mois: +41.67% (0.66)
Changement de prix sur six mois: +31.69% (0.71)
Changement de prix par an: +2.75% (0.91)
Evolution des prix depuis le début de l'année: +26.35% (0.74)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 0.5982 10
P/BV 0.4823 10
P/E 0 0
EV/EBITDA 1.08 10
Total: 6.25

Efficacité

Nom Signification Grade
ROA, % -49.15 0
ROE, % -57.34 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA 0 10
Total: 9.4

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 1.34 1
Rentabilité Ebitda, % -76.95 0
Rentabilité EPS, % -99.75 0
Total: 0.2
Plus de détails

Établissements Volume Partager, %
JBF Capital, Inc. 295000 4.94
Gts Securities LLC 50100 0.84
Virtu Financial LLC 43558 0.73
Geode Capital Management, LLC 41449 0.69
Vanguard Group Inc 23060 0.39
Tower Research Capital LLC (TRC) 10224 0.17
Blackrock Inc. 4790 0.08
Blue Trust, Inc. 916 0.02
Steward Partners Investment Advisory, LLC 709 0.01
Osaic Holdings Inc 43 0



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Albert Nicholas Marchio II CEO, CFO, Secretary & Chairman 251.83k 1952 (73 année)
Aron Aizenstat M.B.A., P.M.P. Vice President of Corporate Development & Operations N/A
Ms. Sue Fattor Head of Human Resource N/A
Dr. James S. McElvain Ph.D. Interim Head of CMC Development N/A
Mr. Aaron Fox-Collis CPA VP of Finance & Chief Accounting Officer N/A

Adresse: United States, Boulder. CO, 5777 Central Avenue - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.frtx.com